Atrium Therapeutics, Inc. Common Stock (NASDAQ:RNA) — Market Cap & Net Worth
Market Cap & Net Worth: Atrium Therapeutics, Inc. Common Stock (RNA)
Atrium Therapeutics, Inc. Common Stock (NASDAQ:RNA) has a market capitalization of $138.86 Million ($138.86 Million) as of September 20, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18032 globally and #4233 in its home market, demonstrating a -13.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Atrium Therapeutics, Inc. Common Stock's stock price $8.95 by its total outstanding shares 15514966 (15.51 Million). Also see balance sheet size of Atrium Therapeutics, Inc. Common Stock for a full breakdown of the balance sheet.
Atrium Therapeutics, Inc. Common Stock Market Cap History: 2020 to 2026
Atrium Therapeutics, Inc. Common Stock's market capitalization history from 2020 to 2026. Data shows change from $395.94 Million to $138.86 Million (-16.86% CAGR). Also see RNA cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Atrium Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.65 Trillion | 0.01% | #502 of 976 |
|
NASDAQ Composite
IXIC
|
$42.12 Trillion | 0.00% | #1759 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.87 Trillion | 0.01% | #236 of 263 |
Weight: Atrium Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Atrium Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Atrium Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Atrium Therapeutics, Inc. Common Stock (RNA) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
60.11x
Atrium Therapeutics, Inc. Common Stock's market cap is 60.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $395.94 Million | $6.79 Million | -$43.98 Million | 58.34x | N/A |
| 2021 | $368.79 Million | $9.33 Million | -$117.37 Million | 39.54x | N/A |
| 2022 | $344.28 Million | $9.22 Million | -$169.08 Million | 37.32x | N/A |
| 2023 | $140.41 Million | $9.56 Million | -$212.22 Million | 14.69x | N/A |
| 2024 | $451.18 Million | $10.90 Million | -$322.30 Million | 41.40x | N/A |
| 2025 | $1.12 Billion | $18.62 Million | -$76.68 Million | 60.11x | N/A |
Competitor Companies of RNA by Market Capitalization
Companies near Atrium Therapeutics, Inc. Common Stock in the global market cap rankings as of September 20, 2026. Review RNA goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Atrium Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Atrium Therapeutics, Inc. Common Stock Historical Marketcap From 2020 to 2026
Between 2020 and today, Atrium Therapeutics, Inc. Common Stock's market cap moved from $395.94 Million to $ 138.86 Million, with a yearly change of -16.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $138.86 Million | -87.59% |
| 2025 | $1.12 Billion | +148.04% |
| 2024 | $451.18 Million | +221.33% |
| 2023 | $140.41 Million | -59.22% |
| 2022 | $344.28 Million | -6.65% |
| 2021 | $368.79 Million | -6.86% |
| 2020 | $395.94 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Atrium Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $138.86 Million USD |
| MoneyControl | $138.86 Million USD |
| MarketWatch | $138.86 Million USD |
| marketcap.company | $138.86 Million USD |
| Reuters | $138.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more